{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:16:54Z","timestamp":1719620214916},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"DOI":"10.7759\/cureus.63364","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:43:44Z","timestamp":1719575024000},"source":"Crossref","is-referenced-by-count":0,"title":["Asciminib Use Highlighting Underlying Moyamoya Disease: A Case Report"],"prefix":"10.7759","author":[{"given":"Saloni","family":"Savani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Pawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naved","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tithi","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samip","family":"Master","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3171\/2009.1.FOCUS08310","article-title":"Moyamoya disease: a summary","volume":"26","author":"Burke GM","year":"2009","unstructured":"Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR. Moyamoya disease: a summary. Neurosurg Focus. 2009, 26:E11. 10.3171\/2009.1.FOCUS08310","journal-title":"Neurosurg Focus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2021.0010","article-title":"Moyamoya disease and syndrome: a review","volume":"55","author":"Demartini Z Jr","year":"2022","unstructured":"Demartini Z Jr, Teixeira BC, Koppe GL, Gatto LA, Roman A, Munhoz RP. Moyamoya disease and syndrome: a review. Radiol Bras. 2022, 55:31-7. 10.1590\/0100-3984.2021.0010","journal-title":"Radiol Bras"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000448314","article-title":"Moyamoya disease","volume":"40","author":"Fujimura M","year":"2016","unstructured":"Fujimura M, Bang OY, Kim JS. Moyamoya disease. Front Neurol Neurosci. 2016, 40:204-20. 10.1159\/000448314","journal-title":"Front Neurol Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014689","article-title":"Asciminib: a new therapeutic option in chronic-phase CML with treatment failure","volume":"139","author":"Yeung DT","year":"2022","unstructured":"Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022, 139:3474-9. 10.1182\/blood.2021014689","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023, 8:262. 10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13944","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study","volume":"26","author":"Chen MT","year":"2021","unstructured":"Chen MT, Huang ST, Lin CW, Ko BS, Chen WJ, Huang HH, Hsiao FY. Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study. Oncologist. 2021, 26:974-82. 10.1002\/onco.13944","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani M","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al.. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013, 122:872-84. 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini S","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, et al.. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011, 118:1208-15. 10.1182\/blood-2010-12-326405","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li MM","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al.. Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017, 19:4-23. 10.1016\/j.jmoldx.2016.10.002","journal-title":"J Mol Diagn"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Radich JP","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, et al.. Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018, 16:1108-35. 10.6004\/jnccn.2018.0071","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, et al.. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019, 381:2315-26. 10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase","volume":"58","author":"Choi EJ","year":"2023","unstructured":"Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. Blood Res. 2023, 58:29-36. 10.5045\/br.2023.2023017","journal-title":"Blood Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3923\/pjbs.2022.175.181","article-title":"Prevalence of BCR-ABL T315I mutation in different chronic myeloid leukemia patients categories","volume":"25","author":"Elsir Khair H","year":"2022","unstructured":"Elsir Khair H, Ahmed Mohamed B, Yousef Nour B, Ali Waggiallah H. Prevalence of BCR-ABL T315I mutation in different chronic myeloid leukemia patients categories. Pak J Biol Sci. 2022, 25:175-81. 10.3923\/pjbs.2022.175.181","journal-title":"Pak J Biol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000328","article-title":"Management of TKI-resistant chronic phase CML","volume":"2022","author":"Hughes TP","year":"2022","unstructured":"Hughes TP, Shanmuganathan N. Management of TKI-resistant chronic phase CML. Hematology Am Soc Hematol Educ Program. 2022, 2022:129-37. 10.1182\/hematology.2022000328","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref15","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","year":"2023","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2023. 8:597219."},{"key":"ref16","article-title":"Moyamoya disease","author":"Rupareliya C","year":"2024","unstructured":"Rupareliya C, Lui F. Moyamoya disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535455\/:"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-023-05858-2","article-title":"Moyamoya disease presenting with symptomatic ischemic stroke during new-generation tyrosine kinase inhibitor treatment: two illustrative cases","volume":"165","author":"Nakajima H","year":"2023","unstructured":"Nakajima H, Miyake R, Hongo T, Takasaki M, Fujimoto Y, Io K. Moyamoya disease presenting with symptomatic ischemic stroke during new-generation tyrosine kinase inhibitor treatment: two illustrative cases. Acta Neurochir (Wien). 2023, 165:3637-41. 10.1007\/s00701-023-05858-2","journal-title":"Acta Neurochir (Wien)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.28189","article-title":"Tyrosine kinase inhibitor toxicity manifesting as comorbid moyamoya syndrome and obstructive coronary artery disease: a case report and review of the literature","volume":"94","author":"Zhuo DX","year":"2019","unstructured":"Zhuo DX, Ragosta M III, Patterson B. Tyrosine kinase inhibitor toxicity manifesting as comorbid moyamoya syndrome and obstructive coronary artery disease: a case report and review of the literature. Catheter Cardiovasc Interv. 2019, 94:117-9. 10.1002\/ccd.28189","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/249981-asciminib-use-highlighting-underlying-moyamoya-disease-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:43:47Z","timestamp":1719575027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/249981-asciminib-use-highlighting-underlying-moyamoya-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.63364","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}